

House Study Bill 164 - Introduced

HOUSE FILE _____
BY (PROPOSED COMMITTEE ON
PUBLIC SAFETY BILL BY
CHAIRPERSON BAUDLER)

A BILL FOR

1 An Act relating to the medical use of cannabidiol including
2 the rescheduling of a cannabidiol investigational product
3 approved as a prescription drug medication under federal law
4 and including effective date provisions.
5 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

1 Section 1. Section 124.201, Code 2017, is amended by adding
2 the following new subsection:

3 NEW SUBSECTION. 5. *a.* If a cannabidiol investigational
4 product approved as a prescription drug medication by the
5 United States food and drug administration is designated
6 as a schedule II controlled substance by the federal drug
7 enforcement agency, the board shall, upon notice of the
8 designation, similarly designate the prescription drug
9 medication as a schedule II controlled substance under this
10 chapter. Such designation by the board shall be immediately
11 effective upon the date of publication in the federal register
12 of the final order designating the prescription drug medication
13 as a schedule II controlled substance.

14 *b.* The board shall adopt rules pursuant to chapter 17A to
15 administer this subsection. The board may adopt rules on an
16 emergency basis as provided in section 17A.4, subsection 3, and
17 section 17A.5, subsection 2, to administer this subsection,
18 and the rules shall be effective immediately upon filing
19 unless a later date is specified in the rules. Any emergency
20 rules adopted in accordance with this subsection shall also be
21 published as a notice of intended action as provided in section
22 17A.4, subsection 1.

23 Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.

24 Sec. 3. EFFECTIVE DATE. The section of this Act repealing
25 section 124D.8, Code 2017, takes effect June 30, 2017.

26 EXPLANATION

27 The inclusion of this explanation does not constitute agreement with
28 the explanation's substance by the members of the general assembly.

29 This bill relates to the medical use of cannabidiol,
30 including the rescheduling of a cannabidiol investigational
31 product approved as a prescription drug medication under
32 federal law.

33 The bill provides if a cannabidiol investigational product
34 approved as a prescription drug medication by the United States
35 food and drug administration is designated as a schedule II

1 controlled substance by the federal drug enforcement agency,
2 the board of pharmacy shall, upon notice of the designation,
3 similarly designate the prescription drug medication as
4 a schedule II controlled substance. Such designation by
5 the board shall be immediately effective upon the date
6 of publication in the federal register of the final order
7 designating the prescription drug medication as a schedule II
8 controlled substance.

9 The bill provides that the board shall adopt rules pursuant
10 to Code chapter 17A to administer the bill and may adopt
11 emergency rules which shall be effective immediately upon
12 filing unless a later date is specified in the rules. Any
13 emergency rules adopted shall also be published as a notice of
14 intended action as provided in Code section 17A.4, subsection
15 1.

16 The bill strikes the repeal of Code chapter 124D (medical
17 cannabidiol Act) before the repeal becomes effective July 1,
18 2017.